Evidence map›Paper›PMID 41419873›Full record

ArticleBMC cancer2025

Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer.

Ryo Yano, Takaaki Tokito, Kenta Murotani, Daiki Murata, Shingo Tsuneyoshi, Hidenobu Ishii, Koichi Azuma, Tomoaki Hoshino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ryo YanoDivision of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
Takaaki TokitoDivision of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan. tokitou_takaaki@kurume-u.ac.jp.
Kenta MurotaniBiostatistics Center, Kurume University, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
Daiki MurataDivision of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
Shingo TsuneyoshiDivision of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
Hidenobu IshiiDivision of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
Koichi AzumaDivision of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
Tomoaki HoshinoDivision of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.

Funding

SPS KAKENHI 19K17688
6 · The paper itself

Abstract

introductionThe standard treatment for stage III non-small cell lung cancer (NSCLC) is platinum-based concurrent chemoradiotherapy (CCRT), followed by durvalumab (anti-programmed death ligand-1 antibody) maintenance therapy. Biomarkers related to immune-related pneumonitis during durvalumab maintenance therapy after CCRT for stage III NSCLC have not yet been identified.

methodsWe evaluated 88 cytokines/chemokines at three time points, before concurrent chemoradiotherapy (pre-CCRT), post-radiotherapy, and six weeks after durvalumab administration, using a multiplex assay (Bio-Plex system) in 29 patients who provided consent for the blood biomarker study, categorizing them into Grade 0–1 and Grade 2 or higher pneumonitis groups.

resultsAt pre-CCRT, no significant changes were observed; however, at post-radiotherapy, significant changes in TNFRSF8/sCD30 were observed in the group with Grade 2 or higher pneumonitis. Moreover, six weeks after durvalumab administration, significant changes were observed in TNFRSF8/sCD30, in addition to TNFSF12, IL-1Ra, CXCL9/CXCL10/CXCL11, IFN-γ, and CCL19.

conclusionAlthough no biomarkers predicting Grade 2 or higher pneumonitis before CCRT were identified, the relationship between radiotherapy and TNFRSF8/sCD30 as well as the relationship between durvalumab administration and various cytokines/chemokines is reported for the first time in stage III NSCLC. In particular, the CXCL family, including CXCL9, CXCL10, and CXCL11, is considered highly significant in pneumonitis with durvalumab maintenance therapy after CCRT for stage III NSCLC. Further large-scale studies are needed to establish biomarkers for patients with NSCLC who receive durvalumab maintenance therapy after CCRT.

Indexed as

Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiomarkers, TumorCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsPneumoniaAgedCytokinesFemaleHumansMaintenance ChemotherapyMaleMiddle AgedNeoplasm StagingAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiomarkers, TumorCytokinesdurvalumabCXCL10CXCL11CXCL9DurvalumabPneumonitisStage III NSCLC

Identifiers

PMID41419873
PMCPMC12831408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.